Colorectal cancer (CRC) is a leading cause of death from cancer in the United States.
In 2010 there are 143,000 new cases of CRC expected with more than 51,000 people dying
from the disease. More than a million individuals worldwide are diagnosed with CRC
every year and half a million die of CRC in the same time period [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics, 2002.CA Cancer J Clin. 2005; 55: 74-108
- Colorectal cancer test use from the 2005 National Health Interview Survey.Cancer Epidemiol Biomarkers Prev. 2008; 17: 1623-1630
- Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.N Engl J Med. 2000; 343: 162-168
- Cost-effectiveness of screening for colorectal cancer in the general population.JAMA. 2000; 284: 1954-1961
- Cost-effectiveness of colonoscopy in screening for colorectal cancer.Ann Intern Med. 2000; 133: 573-584
- Association between colonoscopy rates and colorectal cancer mortality.Am J Gastroenterol. 2010; 105: 1627-1632
- Clinical practice. Screening for colorectal cancer.N Engl J Med. 2009; 361: 1179-1187
- Association of colonoscopy and death from colorectal cancer.Ann Intern Med. 2009; 150: 1-8
- Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study.J Natl Cancer Inst. 2010; 102: 89-95
- Predictors of colorectal cancer after negative colonoscopy: a population-based study.Am J Gastroenterol. 2010; 105 ([quiz: 674]): 663-673
- Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.Lancet. 2010; 375: 1624-1633
- Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial.BMJ. 2009; 338: b1846
- Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence.J Natl Cancer Inst. 2003; 95: 622-625
- A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.N Engl J Med. 1992; 326: 653-657
- Colonoscopy vs sigmoidoscopy screening: getting it right.JAMA. 2010; 304: 461-462
- Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study.Clin Gastroenterol Hepatol. 2008; 6 ([quiz: 1064]): 1117-1121
- The best screening test for colorectal cancer is the one that gets done well.Gastrointest Endosc. 2010; 71: 342-345
- New screening guidelines for colorectal cancer: a practical guide for the primary care physician.Prim Care. 2009; 36: 575-602
- Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice.Gastroenterology. 2008; 135 (1906. e1891): 1899-1906
- Complications of colonoscopy in an integrated health care delivery system.Ann Intern Med. 2006; 145: 880-886
- Risk of perforation from a colonoscopy in adults: a large population-based study.Gastrointest Endosc. 2009; 69: 654-664
- Adverse events after outpatient colonoscopy in the Medicare population.Ann Intern Med. 2009; 150 (W152): 849-857
- Quality indicators for colonoscopy and the risk of interval cancer.N Engl J Med. 2010; 362: 1795-1803
- Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States?.Gastroenterology. 2004; 127: 1661-1669
- The best screening test for colorectal cancer–a personal choice.N Engl J Med. 2000; 343: 1641-1643
- CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.Anticancer Res. 2002; 22: 2311-2316
- Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.Scand J Clin Lab Invest. 1995; 55: 119-124
- Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.Anticancer Res. 2001; 21: 1263-1270
- Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer.Anticancer Res. 1999; 19: 1363-1368
- Evaluation of colorectal cancer-associated mucin CA M43 assay in serum.Clin Chem. 1993; 39: 1029-1032
- Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.Int J Cancer. 1991; 47: 170-179
- The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system.Proc Natl Acad Sci U S A. 1969; 64: 161-167
- Detection of circulating CEA-IgM complexes in early stage colorectal cancer.Int J Biol Markers. 2005; 20: 204-208
- Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.World J Gastroenterol. 2005; 11: 645-648
- Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer.J Clin Endocrinol Metab. 2010; 95: 1717-1725
- Application of cancer procoagulant as an early detection tumor marker.Cancer. 1994; 74: 1367-1376
- Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer.Br J Cancer. 2000; 83: 1139-1146
- The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study.Aliment Pharmacol Ther. 2004; 20: 983-987
- Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.J Immunoassay Immunochem. 2010; 31: 131-147
- Plasma prolactin in patients with colorectal cancer.BMC Cancer. 2004; 4: 97
- Detection of sialylated LewisX antigen in cancer sera using a sandwich radioimmunoassay.Int J Cancer. 1985; 36: 421-425
- Vascular endothelial growth factor (VEGF)–a valuable serum tumour marker in patients with colorectal cancer?.Eur J Surg Oncol. 2001; 27: 37-42
- Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.Dis Colon Rectum. 2006; 49: 883-894
- Circulating insulin-like growth factor II and colorectal adenomas.J Clin Endocrinol Metab. 2000; 85: 3402-3408
- Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.Dig Dis Sci. 2005; 50: 1019-1024
- Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.Int J Oncol. 2005; 26: 65-75
- Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.Gut. 1997; 40: 356-361
- Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?.Cancer Immunol Immunother. 2005; 54: 1038-1042
- Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood–a systematic review.J Surg Res. 2008; 150: 144-152
- Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer.Int J Mol Med. 2006; 17: 737-747
- Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer.Am J Gastroenterol. 2005; 100: 2274-2279
- Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.World J Surg. 2004; 28: 721-726
- Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.Cancer Res. 2001; 61: 2523-2532
- Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer.Colorectal Dis. 2004; 6: 236-242
- Carcinoembryonic gene member 2 mRNA expression as a marker to detect circulating enterocytes in the blood of colorectal cancer patients.Surgery. 2001; 129: 587-594
- Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.Clin Chem. 2001; 47: 505-512
- Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.Clin Cancer Res. 2006; 12: 2095-2100
- Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients.Br J Cancer. 1999; 79: 1813-1820
- Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay.Dis Colon Rectum. 2003; 46: 818-825
- Phases of biomarker development for early detection of cancer.J Natl Cancer Inst. 2001; 93: 1054-1061
- Bol Oficina Sanit Panam. 1968; 65 ([in Spanish]): 281-393
- The effect of fecal occult-blood screening on the incidence of colorectal cancer.N Engl J Med. 2000; 343: 1603-1607
- Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.Am J Gastroenterol. 2008; 103: 1541-1549
- A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.BMJ. 1998; 317: 559-565
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.Lancet. 1996; 348: 1472-1477
- Randomised study of screening for colorectal cancer with faecal-occult-blood test.Lancet. 1996; 348: 1467-1471
- A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.Gut. 2002; 50: 29-32
- Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.Gut. 2010; 59: 62-68
- Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.Ann Intern Med. 2009; 150: 162-169
- Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients.Gastroenterology. 2008; 135: 489-498
- Molecular stool screening for colorectal cancer.Br J Surg. 2004; 91: 790-800
- Genetic alterations during colorectal-tumor development.N Engl J Med. 1988; 319: 525-532
- Allelotype of colorectal carcinomas.Science. 1989; 244: 207-211
- Detection of APC mutations in fecal DNA from patients with colorectal tumors.N Engl J Med. 2002; 346: 311-320
- Stool screening for colorectal cancer: evolution from occult blood to molecular markers.Clin Chim Acta. 2002; 315: 157-168
- Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.N Engl J Med. 2004; 351: 2704-2714
- Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia.Clin Chem. 2006; 52: 2299-2302
- Stool DNA and occult blood testing for screen detection of colorectal neoplasia.Ann Intern Med. 2008; 149 (W481): 441-450
- Accuracy of CT colonography for detection of large adenomas and cancers.N Engl J Med. 2008; 359: 1207-1217
- Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the Medicare population.J Natl Cancer Inst. 2010; 102: 1238-1252
- Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.Gastroenterology. 2008; 134: 1570-1595
- Colorectal cancer screening: a comparison of 35 initiatives in 17 countries.Int J Cancer. 2008; 122: 1357-1367
- Antagonist: population based endoscopic screening for colorectal cancer.Gut. 2003; 52: 323-326
- Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study.Endoscopy. 2006; 38: 963-970
- PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study.Endoscopy. 2006; 38: 971-977
- Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy.Endoscopy. 2009; 41: 1026-1031
- Capsule endoscopy versus colonoscopy for the detection of polyps and cancer.N Engl J Med. 2009; 361: 264-270
- Cost-effectiveness of capsule endoscopy in screening for colorectal cancer.Endoscopy. 2008; 40: 414-421
- The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect.Arch Intern Med. 2003; 163: 1601-1605
- National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening.Ann Intern Med. 2010; 152: 663-667
Article info
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
